|
|
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.
|
|
|
| 2019 | 2020 | Delta | | AUD (in Million) | % | AUD (in Million) | % | | Generic Products | 320.77 | 61.1% | 253.05 | 55.4% | -21.11% | | Metrics Contract Services | 72.20 | 13.7% | 82.82 | 18.1% | +14.71% | | Specialty Brands | 91.56 | 17.4% | 78.76 | 17.2% | -13.98% | | Mayne Pharma International | 40.68 | 7.7% | 42.36 | 9.3% | +4.13% |
|
|
|
| 2019 | 2020 | Delta | | AUD (in Million) | % | AUD (in Million) | % | | United States | 484.55 | 92.3% | 414.63 | 90.7% | -14.43% | | Australia | 28.34 | 5.4% | 28.24 | 6.2% | -0.37% | | Other | 8.87 | 1.7% | 9.31 | 2% | +4.99% | | South Korea | 3.45 | 0.7% | 4.80 | 1.1% | +39.38% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
1,679,068,131 |
1,362,291,673 |
81.1% |
0 |
0.0% |
81.1% |
|
|
|
| Name | Equities | % | | Investors Mutual Ltd. | 146,034,058 |
8.70% | | Bruce L. Mathieson | 105,577,583 |
6.29% | | Lazard Asset Management Pacific Co. | 86,044,209 |
5.12% | | Mithra Pharmaceuticals SA | 83,100,000 |
4.95% | | Dimensional Fund Advisors LP | 43,954,463 |
2.62% | | The Vanguard Group, Inc. | 39,580,987 |
2.36% | | Scott Richards | 34,455,066 |
2.05% | | APG Asset Management NV | 29,660,278 |
1.77% | | Norges Bank Investment Management | 26,833,288 |
1.60% | | Vanguard Investments Australia Ltd. | 19,008,233 |
1.13% |
|
|
|
| Name | Equities | % | Valuation |
| Inhibitor Therapeutics, Inc. (INTI) | 201,842,739 | 54.0% | 7,064,496 USD | | HedgePath Pharmaceuticals, Inc. | 5,797,102 | 100.0% | 202,899 USD |
|
| Company contact information |
|
Mayne Pharma Group Ltd. 1538 Main North Road Salisbury South Salisbury, South Australia (SA) 5106 Phone : +61.8.8209.2666 Fax : +61.8.8281.0284 Web : http://www.maynepharma.com |
|
|
Sector Specialty & Advanced Pharmaceuticals
Connections : Mayne Pharma Group Limited |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
